Overall rank 101 · Score 104 · 2025 May
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
Endocrinology, diabetes & metabolism
Meta-analysisAI-recommended Tier ASafetyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 102 · Score 104 · 2025 Nov
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Obesity (Silver Spring, Md.)
Meta-analysisAI-recommended Tier AWeight loss & obesitySafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 103 · Score 104 · 2025 Sep 1
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.
JAMA ophthalmology
Meta-analysisAI-recommended Tier ASafetyOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 104 · Score 104 · 2025 Dec
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.
EClinicalMedicine
Meta-analysisAI-recommended Tier ADiscontinuation & regainPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 105 · Score 104 · 2023 Mar
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
Obesity (Silver Spring, Md.)
Randomized trialAI-recommended Tier AWeight loss & obesityPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 106 · Score 104 · 2023 Aug 26
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ASafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 107 · Score 104 · 2026 Jan 1
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.
Hepatology (Baltimore, Md.)
Meta-analysisAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 108 · Score 104 · 2026 Jan-Feb
Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Meta-analysisAI-recommended Tier AOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 109 · Score 104 · 2026 Jan
Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Diabetes, obesity & metabolism
Meta-analysisAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 110 · Score 104 · 2026 May
Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.
Ophthalmology
Meta-analysisAI-recommended Tier AOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 111 · Score 104 · 2026 Mar 13
GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
Medicine
Meta-analysisAI-recommended Tier AWeight loss & obesity
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 112 · Score 104 · 2026 Sep
Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Meta-analysisAI-recommended Tier AOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 113 · Score 104 · 2026 Sep 1
Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.
JAMA pediatrics
Meta-analysisAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 114 · Score 104 · 2026 Jul-Aug
Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
La Clinica terapeutica
Meta-analysisAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 115 · Score 104 · 2026 Sep 1
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
JAMA psychiatry
Meta-analysisAI-recommended Tier AWeight loss & obesity
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 116 · Score 104 · 2025 Dec 1
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Hepatology (Baltimore, Md.)
Meta-analysisAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 117 · Score 104 · 2025 Mar
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.
Obesity surgery
Meta-analysisAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 118 · Score 104 · 2025
Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.
PloS one
Meta-analysisAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 119 · Score 104 · 2025 Aug
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
Obesity reviews : an official journal of the International Association for the Study of Obesity
Meta-analysisAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 120 · Score 104 · 2025
Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.
Frontiers in pharmacology
Meta-analysisAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 121 · Score 104 · 2025 May
Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Meta-analysisAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 122 · Score 104 · 2025 Sep 16
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
The Journal of clinical endocrinology and metabolism
Meta-analysisAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 123 · Score 104 · 2025
Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.
Frontiers in endocrinology
Meta-analysisAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 124 · Score 104 · 2025 Jul 6
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.
Scientific reports
Meta-analysisAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 125 · Score 104 · 2025 Sep
Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.
Liver international : official journal of the International Association for the Study of the Liver
Meta-analysisAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.